Understanding how lung cancer evolves resistance to treatments
Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer
['FUNDING_R37'] · CLEVELAND CLINIC LERNER COM-CWRU · NIH-10883460
This study looks at how lung cancer cells with EGFR mutations change and resist treatment, hoping to find new ways to help patients by understanding these changes better.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CLEVELAND CLINIC LERNER COM-CWRU (nih funded) |
| Locations | 1 site (CLEVELAND, UNITED STATES) |
| Trial ID | NIH-10883460 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind therapy resistance in EGFR-driven lung cancer by examining the ecological and evolutionary processes within tumors. It employs a combination of mathematical modeling and experimental techniques to analyze how cancer cells interact and evolve in response to treatment. By focusing on the dynamics of these interactions, the research aims to identify new strategies for drug design that could prevent or delay resistance. Patients with EGFR mutations in non-small cell lung cancer may benefit from insights gained through this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with EGFR-mutated non-small cell lung cancer.
Not a fit: Patients with lung cancer that does not involve EGFR mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively prevent resistance in lung cancer therapies.
How similar studies have performed: While the focus on eco-evolutionary processes in cancer is relatively novel, similar approaches in understanding drug resistance have shown promise in other cancer types.
Where this research is happening
CLEVELAND, UNITED STATES
- CLEVELAND CLINIC LERNER COM-CWRU — CLEVELAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCOTT, JACOB GARDINIER — CLEVELAND CLINIC LERNER COM-CWRU
- Study coordinator: SCOTT, JACOB GARDINIER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer research, Cancer Cause, cancer cell, Cancer Etiology, cancer progression